Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for advances in Alzheimer’s disease made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in -
USC’s Minority Aging Research Center Secures $3.6M for Alzheimer’s Research
Researchers study the health and economics issues associated with cognitive decline and dementia, and particularly the inequitable burden of Alzheimer’s.
Posted in -
Healthcare Utilization Before and After a Dementia Diagnosis in Medicare Advantage Versus Traditional Medicare
The increase in care use leading up to a dementia diagnosis is higher among beneficiaries in traditional Medicare than in Advantage plans and remains higher after diagnosis.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
Estimates of Diagnosed Dementia Prevalence and Incidence Among Diverse Beneficiaries in Traditional Medicare and Medicare Advantage
The prevalence of diagnosed dementia among beneficiaries in MA was lower than in TM.
-
Blood Pressure Medication and Dementia Prevention: The Promising Link
SC Schaeffer Center researchers have turned to real-world data to probe the relationship between antihypertensive use and dementia risk in the U.S. population and among minoritized populations who are at the highest risk of dementia.
Categorized in -
The Agency Keeping Alzheimer’s Drugs from Patients
The Centers for Medicare and Medicaid Services refuses to approve breakthrough drugs.
Categorized in -
Medicare’s ‘Coverage with Evidence Development’: A Barrier to Patient Access and Innovation
CMS should abandon CED or, at minimum, reform and restrict its use only for off-label applications of therapies.
Categorized in -
Expanding the Use of Brief Cognitive Assessments to Detect Suspected Early-Stage Cognitive Impairment in Primary Care
Providing primary care clinicians with suitable assessment tools, integrating brief cognitive assessments into routine workflows, and crafting payment policies to encourage adoption of assessments would all help improve detection.
Categorized in
